Evaluate Safety of T/I on Diabetic Subjects With Mild Obstructive Pulmonary Disease

Inclusion Criteria:

• Clinical diagnosis of Type1or2 diabetes for 12 months and no change in anti-diabetic regiment for at least 90-days prior to screening
• BMI of 35 kg/m2. A1C 7.0% - 11.0%
• Non-smoker & urine cotinin level <100ng/dL
• Clinical diagnosis of obstructive lung disease

Exclusion Criteria:

• History of pulmonary exacerbation with 8 wks of screening/V1
• Post-brochhodilator FEV1 <50%, FVC <70% NHANES III predicted, peformed at the clinical site using office spirometry
• History of systemic corticosteriod or antibiotic use of respiratory illness within 8 weeks of V1
• Treatment with >4 puffs or >2 nebulizer treatments.day of inhaled short-acting beta agonist or shorty-acting anti-cholingeric agents of a combination of the 2.
• Treatment with supplemental oxygen therapy, room air oxygen saturation, 94% or history of intubation or ICU admission for respiratory illness in the past 5 yrs.
• Greater than 2 hospitalizations or ER visits or required >3 courses of systemic steriod in the past 12 mos. for respiratory illness